MDxHealth SA (NASDAQ/Euronext: MDXH), a leading commercial-stage precision diagnostics company, today announced a research collaboration with the Universit...
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (OR...
“We are thrilled to receive marketing approval for AVT04 in Japan, which will be Alvotech’s second marketed biosimilar,” said Robert Wess...
Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational ...
QIAGEN announced the extension of its eco-friendlier QIAwave product line with the addition of two new nucleic acid extraction kits: the QIAwave RNeasy Plu...
In the world of biotechnology and pharmaceuticals, innovation is the lifeblood of progress. And in the picturesque Basel area, this spirit of innovation is...
The healthcare landscape in Latin America is currently a worldwide priority. Factors such as increasing awareness of precision medicine, the growing preval...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluatin...
CBM brings extensive cell and gene therapy expertise to SK pharmteco portfolio and continues SK pharmteco’s strategy to deliver end-to-end, multi-mod...
-Zelis, a healthcare technology company modernizing the healthcare financial experience for all, today announced that its payer clients can now offer their...
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa Spain-based gl...
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced that the European Unified Patent Court ("UPC") issued a...
The primary objective is to evaluate VISTA as a biomarker to guide patient selection and treatment optimization for VISTA-targeted therapies where no stand...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, announced a new study as part of the I-SPY 2 trial, sponsored and operated by ...
© 2025 Biopharma Boardroom. All Rights Reserved.
